Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)(HR-NBL2)
Protocol ID
HR NBL2
Disease (Sub Disease)
Neuroblastoma
Diagnosis Stage
Newly diagnosed
Location
NSW, VIC
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
Links
Trial Status
Open
Sites
John Hunter Children's Hospital
Sydney Children's Hospital
Monash Children's Hospital
Sydney Children's Hospital
Monash Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 20 years
International registry ID's
NCT04221035
| Study Title | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)(HR-NBL2) |
|---|---|
| Protocol ID | HR NBL2 |
| Disease (Sub Disease) | Neuroblastoma |
| Diagnosis Stage | Newly diagnosed |
| Location | NSW / VIC |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group |
| Collaborators | Gustave Roussy, Cancer Campus, Grand Paris/ |
| Links | https://clinicaltrials.gov/ct2/show/NCT04221035 |
| Trial Status | Open |
| Trial Open Date | 31/03/2023 |
| Sites | John Hunter Children's Hospital/ Sydney Children's Hospital / Monash Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 20 years |
| International registry ID's | NCT04221035 |